All In Biotech

Drug Trial Radar · NCT05691491

Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness

A Phase 1/2 Trial Evaluating the Combination of Temozolomide and the Ataxia Telangiectasia and Rad3-Related Inhibitor M1774

Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

42

Planned (sponsor's estimate)

Start

Sep 28, 2023

Primary completion

Mar 1, 2027

Study completion Mar 1, 2027

Sponsor

Sponsor type
NIH
First posted
Jan 20, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase I/II trial studies the side effects and best dose of temozolomide and M1774 and how well they works in treating patients with cancer that has spread from where it first started (primary site) to other places in the body (metastatic) and may have spread to nearby tissue, lymph nodes, or distant parts of the body (advanced). Temozolomide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill tumor cells and slow down or stop tumor growth. M1774 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Adding M1774 to temozolomide may shrink or stabilize cancer for longer than temozolomide alone.

Conditions

  • Advanced Malignant Solid Neoplasm
  • Advanced Microsatellite Stable Colorectal Carcinoma
  • Hematopoietic and Lymphatic System Neoplasm
  • Metastatic Malignant Solid Neoplasm
  • Metastatic Microsatellite Stable Colorectal Carcinoma
  • Stage III Colorectal Cancer AJCC v8
  • Stage IV Colorectal Cancer AJCC v8

Interventions

  • Biopsy ProcedureProcedure

    Undergo biopsy

  • Biospecimen CollectionProcedure

    Undergo collection of blood samples

  • Computed TomographyProcedure

    Undergo CT scan

  • Magnetic Resonance ImagingProcedure

    Undergo MRI

  • TemozolomideDrug

    Given orally (PO)

  • TuvusertibDrug

    Given PO

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose limiting toxicity and the maximum tolerated doseTime frame: Up to 28 days

Locations

23 sites in 1 country. Site status is shown where the registry gives one.

  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care

    Irvine, California

  • UC San Diego Moores Cancer Center

    La Jolla, California

  • UC Irvine Health/Chao Family Comprehensive Cancer Center

    Orange, California

  • Yale University

    New Haven, Connecticut

  • Smilow Cancer Hospital Care Center-Trumbull

    Trumbull, Connecticut

  • Memorial Hospital East

    Shiloh, Illinois

  • University of Kansas Clinical Research Center

    Fairway, Kansas

  • University of Kansas Cancer Center

    Kansas City, Kansas

  • University of Kansas Cancer Center-Overland Park

    Overland Park, Kansas

  • University of Kansas Hospital-Indian Creek Campus

    Overland Park, Kansas

  • University of Kansas Hospital-Westwood Cancer Center

    Westwood, Kansas

  • National Cancer Institute Developmental Therapeutics Clinic

    Bethesda, Maryland

  • Siteman Cancer Center at Saint Peters Hospital

    City of Saint Peters, Missouri

  • Siteman Cancer Center at West County Hospital

    Creve Coeur, Missouri

  • University of Kansas Cancer Center - North

    Kansas City, Missouri

  • University of Kansas Cancer Center - Lee's Summit

    Lee's Summit, Missouri

  • University of Kansas Cancer Center at North Kansas City Hospital

    North Kansas City, Missouri

  • Washington University School of Medicine

    St Louis, Missouri

  • Siteman Cancer Center-South County

    St Louis, Missouri

  • Siteman Cancer Center at Christian Hospital

    St Louis, Missouri

  • University of Oklahoma Health Sciences Center

    Oklahoma City, Oklahoma

  • UPMC Hillman Cancer Center

    Pittsburgh, Pennsylvania

  • Vanderbilt University/Ingram Cancer Center

    Nashville, Tennessee

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.